Physician profile
James Russell
NPI 1841371978
$868.48
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.00 · 2021: $240 · 2022: $387 · 2024: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $150 · Food and Beverage: $58.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $150.00 |
| Food and Beverage | $58.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $225.29 | 2022-2024 | Ultomiris |
| Boston Scientific Corporation | $218.71 | 2021 | |
| Argenx US, INC. | $86.67 | 2022-2024 | Vyvgart |
| Novartis Pharmaceuticals Corporation | $54.08 | 2022 | |
| Genentech, INC. | $53.99 | 2019-2021 | |
| Biogen, INC. | $41.82 | 2022 | |
| Lilly USA, LLC | $38.20 | 2022 | |
| Kyowa Kirin, INC. | $31.38 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.26 | 2022 | |
| Abbvie INC. | $26.15 | 2022 | |
| Neurelis, INC. | $25.81 | 2022 | |
| Celgene Corporation | $21.05 | 2022 | |
| Amgen INC. | $19.07 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.